Less than 10% of individuals who could benefit from obesity jabs including Wegovy have access to them, caution the WHO as it releases its inaugural recommendations on the medications.
Given in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is urging more widespread and fairer availability to this class of drugs.
According to estimates, in excess of 2,000,000,000 are projected to be living with obesity by 2030 unless action is taken.
"The latest guidelines affirms that obesity is a lifelong illness that can be treated with holistic and continuous treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are key barriers to universal access to the jabs that can help people shift substantial weight, says the agency.
Skinny Jab Shortage
Despite the current most optimistic scenario, the production of such drugs might only reach about 100 million people – less than 10% of those who need them, as stated by the health organization.
The recommendation urges nations and manufacturers to widen availability, by strategies like voluntary licensing.
Exclusive production rights on the active ingredient – the primary component of the drug Wegovy – is scheduled to end in a number of nations in 2026.
How Obesity Drugs Function
The injections replicate a body's own hormone to slow digestion, curb appetite and enhance feelings of fullness so people reduce food intake.
Individuals typically see weight reduction in the initial weeks of commencing the once-weekly jabs.
Evidence points to patients may regain a significant portion within a year of halting the treatment, as their typical food cravings resume.
To be carrying excess weight raises your chance for developing diseases, such as type 2 diabetes, heart disease, brain attack, and specific malignancies.
Obesity concerns individuals in countries worldwide and was linked to over three and a half million fatalities worldwide in 2024, as per the health agency.
